The heart in sepsis: From basic mechanisms to clinical management

Current Vascular Pharmacology

Volumn 11, Issue 2, 2013, Pages 187-195

  Rudiger, Alain ^a   Singer, Mervyn ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Adrenergic stimulation; Beta blocker; Early goal directed therapy; Esmolol; Heart; Inflammation; Levosimendan; Sepsis

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR; CALCIUM CHANNEL BLOCKING AGENT; CATECHOLAMINE; DOBUTAMINE; DOPAMINE; ESMOLOL; GLUCOSE; HYPERTENSIVE FACTOR; INSULIN; INTERLEUKIN 6; ISTAROXIME; IVABRADINE; LEVOSIMENDAN; MILRINONE; NITRIC OXIDE; NORADRENALIN; OMECAMTIV MECARBIL; TUMOR NECROSIS FACTOR ALPHA; VASODILATOR AGENT; VASOPRESSIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ARTICLE; CARDIOMYOPATHY; DRUG MEGADOSE; HEART; HEART ARRHYTHMIA; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CONTRACTILITY; HEART PRELOAD; HUMAN; HYPOTENSION; METABOLISM; MULTIPLE ORGAN FAILURE; NONHUMAN; SEPSIS; SEPTIC SHOCK; SURVIVAL; ANIMAL; CARDIOMYOPATHIES; DISEASE MANAGEMENT; DRUG EFFECTS; MICROCIRCULATION; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CARDIOMYOPATHIES; DISEASE MANAGEMENT; HUMANS; MICROCIRCULATION; SEPSIS;

EID: 84875322241     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016113805290227     Document Type: Article

References (171)

1. Beutler B, Hoebe K, Du X, Ulevitch RJ. How we detect microbes and respond to them: the Toll-like receptors and their transducers. J Leukoc Biol 2003; 74: 479-85.
2. Annane D, Bellissant E, Cavaillon J-M. Septic shock. Lancet 2005; 365: 63-78.
3. Tsujimoto H, Ono S, Efron PA, Scumpia PO, Moldawer LL, Mochizuki H. Role of Toll-like receptors in the development of sepsis. Shock 2008; 29: 315-21.
4. Calvano SE, Xiao W, Richards DR, et al. A network-based analysis of systemic inflammation in humans. Nature 2005; 437: 1032-7.
5. Rudiger A, Stotz M, Singer M. Cellular processes in sepsis. Swiss Med Wkly 2008; 138: 629-34.
6. Rivers E, Nguyen B, Havstad S, et al. Early-goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345: 1368-77.
7. De Backer D, Creteur J, Preiser J-C, Dubois M-J, Vincent J-L. Microvascular blood flow is altered in patients with sepsis. Am J Respir Crit Care Med 2002; 166: 98-104.
8. Sakr Y, Dubois M-J, De Backer D, Creteur J, Vincent J-L. Persistent microcirculatory alterations are associated with organ failure and death in patients with septic shock. Crit Care Med 2004; 32: 1825-31.
9. Ait-Oufella H, Maury E, Lehoux S, Guidet B, Offenstadt G. The endothelium: physiological functions and role in microcirculatory failure during severe sepsis. Intensive Care Med 2010; 36: 1286-98.
10. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003; 425: 516-21.
11. Lotze MT, Deisseroth A, Rubartelli A. Damage associated molecular pattern molecules. Clin Immunol 2007; 124: 1-4.
12. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007; 81: 1-5.
13. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348: 1546-54.
14. Annane D, Aegerter P, Jars-Guincestre MC, Guidet B. Current epidemiology of septic shock: the CUB-Rea Network. Am J Respir Crit Care Med 2003; 168: 165-72.
15. Sorensen TI, Nielsen GG, Andersen PK, Teasdale TW. Genetic and environmental influences on premature death in adult adoptees. N Engl J Med 1988; 318: 727-32.
16. Lukaszewicz AC, Payen D. The future is predetermined in severe sepsis, so what are the implications? Crit Care Med 2010; 38: S512-7.
17. Singer M, Glynne P. Treating critical illness: The importance of first doing no harm. PLoS Med 2005; 2: e167.
18. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348: 138-50.
19. Dyson A, Rudiger A, Singer M. Temporal changes in tissue cardiorespiratory function during faecal peritonitis. Intensive Care Med 2011; 37: 1192-200.
20. Annane D, Trabold F, Sharshar T, et al. Inappropriate sympathetic activation at onset of septic shock: a spectral analysis approach. Am J Respir Crit Care Med 1999; 160: 458-65.
21. Korach M, Sharshar T, Jarrin I, et al. Cardiac variability in critically ill adults: influence of sepsis. Crit Care Med 2001; 29: 1380-5.
22. Schmidt H, Müller-Werdan U, Hoffmann T, et al. Autonomic dysfunction predicts mortality in patients with multiple organ dysfunction syndrome of different age groups. Crit Care Med 2005; 33: 1994-2002.
23. Rudiger A, Fischler M, Harpes P, et al. In critically ill patients, Btype natriuretic peptide (BNP) and N-terminal pro-BNP levels correlate with C-reactive protein values and leukocyte counts. Int J Cardiol 2008; 126: 28-31.
24. Singer M. Metabolic failure. Crit Care Med 2005; 33: 539-42.
25. Brealey D, Brand M, Hargreaves I, et al. Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet 2002; 360: 219-23.
26. Brealey D, Karyampudi S, Jacques TS, et al. Mitochondrial dysfunction in a long-term rodent model of sepsis and organ failure. Am J Physiol Regul Integr Comp Physiol 2004; 286: R491-7.
27. Suliman HB, Carraway MS, Piantadosi CA. Postlipopolysaccharide oxidative damage of mitochondrial DNA. Am J Respir Crit Care Med 2003; 167: 570-9.
28. Suliman HB, Welty-Wolf KE, Carraway MS, Tatro L, Piantadosi CA. Lipopolysaccharide induces oxidative cardiac mitochondrial damage and biogenesis. Cardiovasc Res 2004; 64: 279-88.
29. Singer M, De Santis V, Vitale D, Jeffcoate W. Multiorgan failure is an adaptive, endocrine-mediated, metabolic response to overwhelming systemic inflammation. Lancet 2004; 364: 545-8.
30. Rudiger A. Beta-block the septic heart. Crit Care Med 2010; 38: S608-12.
31. Brun C, Munck O. Lesions of the kidney in acute renal failure following shock. Lancet 1957; 272: 603-7.
32. Hotchkiss RS, Swanson PE, Freeman BD, et al. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med 1999; 27: 1230-51.
33. Rossi MA, Celes MR, Prado CM, Saggioro FP. Myocardial structural changes in long-term human severe sepsis/septic shock may be responsible for cardiac dysfunction. Shock 2007; 27: 10-8.
34. Carré JE, Orban JC, Re L, et al. Survival in critical illness is associated with early activation of mitochondrial biogenesis. Am J Respir Crit Care Med 2010; 182: 745-51.
35. Rudiger A, Singer M. Mechanisms of sepsis-induced cardiac dysfunction. Crit Care Med 2007; 35: 1599-608.
36. Jones AE, Craddock PA, Tayal VS, Kline JA. Diagnostic accuracy of left ventricular function for identifying sepsis among emergency department patients with nontraumatic symptomatic undifferentiated hypotension. Shock 2005; 24: 513-7.
37. Jardin F, Fourme T, Page B, et al. Persistent preload defect in severe sepsis despite fluid loading: A longitudinal echocardiographic study in patients with septic shock. Chest 1999; 116: 1354-9.
38. Parker MM, Shelhamer JH, Bacharach SL, et al. Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med 1984; 100: 483-90.
39. Poelaert J, Declerck C, Vogelaers D, Colardyn F, Visser CA. Left ventricular systolic and diastolic function in septic shock. Intensive Care Med 1997; 23: 553-60.
40. Bouhemad B, Nicolas-Robin A, Arbelot C, Arthaud M, Feger F, Rouby JJ. Isolated and reversible impairment of ventricular relaxation in patients with septic shock. Crit Care Med 2008; 36: 766-74.
41. Ikonomidis I, Nikolaou M, Dimopoulou I, et al. Association of left ventricular diastolic dysfunction with elevated NT-pro-BNP in general intensive care unit patients with preserved ejection fraction: a complementary role of tissue Doppler imaging parameters and NT-pro-BNP levels for adverse outcome. Shock 2010; 33: 141-8.
42. Sturgess DJ, Marwick TH, Joyce C, et al. Prediction of hospital outcome in septic shock: a prospective comparison of tissue Doppler and cardiac biomarkers. Crit Care 2010; 14: R44.
43. Landesberg G, Gilon D, Meroz Y, et al. Diastolic dysfunction and mortality in severe sepsis and septic shock. Eur Heart J 2012; 33(7): 895-03.
44. Goodman S, Weiss Y, Weissman C. Update on cardiac arrhythmias in the ICU. Curr Opin Crit Care 2008; 14: 549-54.
45. Leibovici L, Gafter-Gvili A, Paul M, et al. Relative tachycardia in patients with sepsis: an independent risk factor for mortality. Qjm 2007; 100: 629-34.
46. Parker MM, McCarthy KE, Ognibene FP, Parrillo JE. Right ventricular dysfunction and dilatation, similar to left ventricular changes, characterize the cardiac depression of septic shock in humans. Chest 1990; 97: 126-31.
47. Vieillard-Baron A, Prin S, Chergui K, Dubourg O, Jardin F. Hemodynamic instability in sepsis. Am J Respir Crit Care Med 2003; 168: 1270-6.
48. Spies C, Haude V, Fitzner R, et al. Serum cardiac troponin T as a prognostic marker in early sepsis. Chest 1998; 113: 1055-63.
49. Ammann P, Fehr T, Minder EI, Gunter C, Bertel O. Elevation of troponin I in sepsis and septic shock. Intensive Care Med 2001; 27: 965-9.
50. Witthaut R, Busch C, Fraunberger P, et al. Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: impact of interleukin-6 and sepsis-associated left ventricular dysfunction. Intensive Care Med 2003; 29: 1696-702.
51. Charpentier J, Luyt C-E, Fulla Y, et al. Brain natriuretic peptide: a marker of myocardial dysfunction and prognosis during severe sepsis. Crit Care Med 2004; 32: 660-5.
52. Rudiger A, Gasser S, Fischler M, Hornemann T, Von Eckardstein A, Maggiorini M. Comparable increase of B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide levels in patients with severe sepsis, septic shock, and acute heart failure. Crit Care Med 2006; 34: 2140-4.
53. Levy RJ, Deutschman CS. Evaluating myocardial depression in sepsis. Shock 2004; 22: 1-10.
54. Rabuel C, Mebazaa A. Septic shock: a heart story since the 1960s. Intensive Care Med 2006; 32: 799-807.
55. Tavener SA, Kubes P. Cellular and molecular mechanisms underlying LPS-associated myocyte impairment. Am J Physiol Heart Circ Physiol 2006; 290: H800-H6.
56. Merx MW, Weber C. Sepsis and the heart. Circulation 2007; 116: 793-802.
57. Flierl MA, Rittirsch D, Huber-Lang MS, Sarma JV, Ward PA. Molecular events in the cardiomyopathy of sepsis. Mol Med 2008; 14: 327-36.
58. Court O, Kumar A, Parrillo JE, Kumar A. Myocardial depression in sepsis and septic shock. Crit Care 2002; 6: 500-7.
59. Fernandes CJ, Jr., Akamine N, Knobel E. Myocardial depression in sepsis. Shock 2008; 30 (Suppl 1): 14-7.
60. Kovarik MF, Jones SB, Romano FD. Plasma catecholamines following cecal ligation and puncture in the rat. Circ Shock 1987; 22: 281-90.
61. Boldt J, Menges T, Kuhn D, Diridis C, Hempelmann G. Alterations in circulating vasoactive substances in the critically ill--a comparison between survivors and non-survivors. Intensive Care Med 1995; 21: 218-25.
62. Zhou M, Das P, Simms HH, Wang P. Gut-derived norepinephrine plays an important role in up-regulating IL-1beta and IL-10. Biochim Biophys Acta 2005; 1740: 446-52.
63. Bergquist J, Tarkowski A, Ekman R, Ewing A. Discovery of endogenous catecholamines in lymphocytes and evidence for catecholamine regulation of lymphocyte function via an autocrine loop. Proc Natl Acad Sci USA 1994; 91: 12912-6.
64. Musso NR, Brenci S, Setti M, Indiveri F, Lotti G. Catecholamine content and in vitro catecholamine synthesis in peripheral human lymphocytes. J Clin Endocrinol Metab 1996; 81: 3553-7.
65. Marino F, Cosentino M, Bombelli R, Ferrari M, Lecchini S, Frigo G. Endogenous catecholamine synthesis, metabolism storage, and uptake in human peripheral blood mononuclear cells. Exp Hematol 1999; 27: 489-95.
66. Flierl MA, Rittirsch D, Nadeau BA, et al. Phagocyte-derived catecholamines enhance acute inflammatory injury. Nature 2007; 449: 721-5.
67. Cosentino M, Marino F, Bombelli R, Ferrari M, Lecchini S, Frigo G. Endogenous catecholamine synthesis, metabolism, storage and uptake in human neutrophils. Life Sci 1999; 64: 975-81.
68. Tang C, Liu M-S. Internal externalization followed by internalization of β-adrenergic receptors in rat heart during sepsis. Am J Physiol Regul Integr Comp Physiol 1996; 270: 254-63.
69. Tang C, Yang J, Wu LL, Dong LW, Liu MS. Phosphorylation of beta-adrenergic receptor leads to its redistribution in rat heart during sepsis. Am J Physiol 1998; 274: R1078-86.
70. Böhm M, Kirchmayr R, Gierschik P, Erdmann E. Increase of myocardial inhibitory G-proteins in catecholamine-refractory septic shock or in septic multiorgan failure. Am J Med 1995; 98: 183-6.
71. Bernardin G, Strosberg AD, Bernard A, Mattei M, Marullo S. β-adrenergic receptor-dependent and-independent stimulation of adenylate cyclase is impaired during severe sepsis in humans. Intensive Care Med 1998; 24: 1315-22.
72. Wu L-L, Yang S-L, Yang R-C, et al. G protein and adenylate cyclase complex-mediated signal transduction in the rat heart during sepsis. Shock 2003; 19: 533-7.
73. Matsuda N, Hattori Y, Akaishi Y, Suzuki Y, Kemmotsu O, Gando S. Impairment of cardiac β-adrenoceptor cellular signaling by decreased expression of Gsα in septic rabbits. Anesthesiology 2000; 93: 1465-73.
74. Gulick TS, Chung MK, Pieper SJ, Lange LG, Schreiner GF. Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness. Proc Natl Acad Sci USA 1989; 86: 6753-7.
75. Chung MK, Gulick TS, Rotondo RE, Schreiner GF, Lange LG. Mechanism of cytokine inhibition of beta-adrenergic agonist stimulation of cyclic AMP in rat cardiac myocytes. Impairment of signal transduction. Circ Res 1990; 67: 753-63.
76. Hare JM, Keaney JF, Jr., Balligand J-L, Loscalzo J, Smith TW, Colucci WS. Role of nitric oxide in parasympathetic modulation of beta-adrenergic myocardial contractility in normal dogs. J Clin Invest 1995; 95: 360-6.
77. Barth E, Radermacher P, Thiemermann C, Weber S, Georgieff M, Albuszies G. Role of inducible nitric oxide synthase in the reduced responsiveness of the myocardium to catecholamines in a hyperdynamic, murine model of septic shock. Crit Care Med 2006; 34: 307-13.
78. Sharshar T, Gray F, Lorin de la Grandmaison G, et al. Apoptosis of neurons in cardiovascular autonomic centres triggered by inducible nitric oxide synthase after death from septic shock. Lancet 2003; 362: 1799-805.
79. Macarthur H, Westfall TC, Riley DP, Misko TP, Salvemini D. Inactivation of catecholamines by superoxide gives new insights on the pathogenesis of septic shock. Proc Natl Acad Sci USA 2000; 97: 9753-8.
80. Parrillo JE, Burch C, Shelhamer JH, Parker MM, Natanson C, Schuette W. A circulating mycoardial depressant substance in humans with septic shock. J Clin Invest 1985; 76: 1539-53.
81. Suzuki T, Morisaki H, Serita R, et al. Infusion of the β-adrenergic blocker esmolol attenuates myocardial dysfunction in septic rats. Crit Care Med 2005; 33: 2294-301.
82. Cariou A, Pinsky MR, Monchi M, et al. Is myocardial adrenergic responsiveness depressed in human septic shock? Intensive Care Med 2008; 34: 917-22.
83. Hollenberg SM, Dumasius A, Easington C, Colilla SA, Neumann A, Parrillo JE. Characterization of a hyperdynamic murine model of resuscitated sepsis using echocardiography. Am J Respir Crit Care Med 2001; 164: 891-5.
84. Liu S, Schreur KD. G protein-mediated suppression of L-type Ca2+ current by interleukin-1 beta in cultured rat ventricular myocytes. Am J Physiol Cell Physiol 1995; 268: 339-49.
85. Zhong J, Hwang T-C, Adams HR, Rubin LJ. Reduced L-type calcium current in ventricular myocytes from endotoxemic guinea pigs. Am J Physiol Heart Circ Physiol 1997; 273: 2312-24.
86. Abi-Gerges N, Tavernier B, Mebazaa A, et al. Sequential changes in autonomic regulation of cardiac myocytes after in vivo endotoxin injection in rat. Am J Respir Crit Care Med 1999; 160: 1196-204.
87. Stengl M, Bartak F, Sykora R, et al. Reduced L-type calcium current in ventricular myocytes from pigs with hyperdynamic septic shock. Crit Care Med 2010; 38: 579-87.
88. Wu L-L, Liu M-S. Altered ryanodine receptor of canine cardiac sarcoplasmic reticulum and its underlying mechanism in endotoxin shock. J Surg Res 1992; 53: 82-90.
89. Dong LW, Wu LL, Ji Y, Liu MS. Impairment of the ryanodinesensitive calcium release channels in the cardiac sarcoplasmic reticulum and its underlying mechanism during the hypodynamic phase of sepsis. Shock 2001; 16: 33-9.
90. Cohen RI, Wilson D, Liu SF. Nitric oxide modifies the sarcoplasmic reticular calcium release channel in endotoxemia by both guanosine-3',5' (cyclic) phosphate-dependent and independent pathways. Crit Care Med 2006; 34: 173-81.
91. Wu L-L, Tang C, Dong L-W, Liu M-S. Altered phospholambancalcium ATPase interaction in cardiac sarcoplasmic reticulum during the progression of sepsis. Shock 2002; 17: 389-93.
92. Wu L-L, Ji Y, Dong L-W, Liu M-S. Calcium uptake by sarcoplasmic reticulum is impaired during the hypodynamic phase of sepsis in the rat heart. Shock 2001; 15: 49-55.
93. Takeuchi K, del Nido PJ, Ibrahim AE, et al. Increased myocardial calcium cycling and reduced myofilament calcium sensitivity in early endotoxemia. Surgery 1999; 126: 231-8.
94. Wu L-L, Tang C, Liu M-S. Altered phosphorylation and calcium sensitivity of cardiac myofibrillar proteins during sepsis. Am J Physiol Regul Integr Comp Physiol 2001; 281: R408-R16.
95. 2+ sensitivity but normal mitochondrial function in septic heart. Am J Respir Crit Care Med 2001; 163: 362-7.
96. Rudiger A, Dyson A, Felsmann K, et al. Early functional and transcriptomic changes in the myocardium predict outcome in a longterm rat model of sepsis. Clin Sci (Lond) 2013; 124: 391-401.
97. dos Santos CC, Gattas DJ, Tsoporis JN, et al. Sepsis-induced myocardial depression is associated with transcriptional changes in energy metabolism and contractile related genes: a physiological and gene expression-based approach. Crit Care Med 2010; 38: 894-902.
98. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34: 1589-96.
99. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008; 34: 17-60.
100. Vincent JL, Weil MH. Fluid challenge revisited. Crit Care Med 2006; 34: 1333-7.
101. Boyd JH, Forbes J, Nakada TA, Walley KR, Russell JA. Fluid resuscitation in septic shock: a positive fluid balance and elevated central venous pressure are associated with increased mortality. Crit Care Med 2011; 39: 259-65.
102. Ritter S, Rudiger A, Maggiorini M. Transpulmonary thermodilution-derived cardiac function index identifies cardiac dysfunction in acute heart failure and septic patients: an observational study. Crit Care 2009; 13: 1003.
103. Brunkhorst FM, Engel C, Bloos F, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008; 358: 125-39.
104. Schortgen F, Girou E, Deye N, Brochard L. The risk associated with hyperoncotic colloids in patients with shock. Intensive Care Med 2008; 34: 2157-68.
105. Honore PM, Joannes-Boyau O, Boer W. Hyperoncotic colloids in shock and risk of renal injury: enough evidence for a banning order? Intens Care Med 2008; 34: 2127-9.
106. Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004; 350: 2247-56.
107. Jones AE, Shapiro NI, Trzeciak S, Arnold RC, Claremont HA, Kline JA. Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial. JAMA 2010; 303: 739-46.
108. Annane D, Vignon P, Renault A, et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet 2007; 370: 676-84.
109. Singer M. Catecholamine treatment for shock--equally good or bad? Lancet 2007; 370: 636-7.
110. Hayes MA, Timmins AC, Yau E, Palazzo M, Hinds CJ, Watson D. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med 1994; 330: 1717-22.
111. Gattinoni L, Brazzi L, Pelosi P, et al. A trial of goal-oriented hemodynamic therapy in critically ill patients. N Engl J Med 1995; 333: 1025-32.
112. Schmittinger CA, Dünser MW, Haller M, et al. Combined milrinone and enteral metoprolol therapy in patients with septic myocardial depression. Crit Care 2008; 12: R99.
113. Cuffe MS, Califf RM, Adams KF, Jr., et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002; 287: 1541-7.
114. Patel GP, Grahe JS, Sperry M, et al. Efficacy and safety of dopamine versus norepinephrine in the management of septic shock. Shock 2010; 33: 375-80.
115. De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2011; 362: 779-89.
116. Beale RJ, Hollenberg SM, Vincent JL, Parrillo JE. Vasopressor and inotropic support in septic shock: an evidence-based review. Crit Care Med 2004; 32: S455-65.
117. Dünser MW, Ruokonen E, Pettila V, et al. Association of arterial blood pressure and vasopressor load with septic shock mortality: a post hoc analysis of a multicenter trial. Crit Care 2009; 13: R181.
118. Barrett LK, Singer M, Clapp LH. Vasopressin: mechanisms of action on the vasculature in health and in septic shock. Crit Care Med 2007; 35: 33-40.
119. Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008; 358: 877-87.
120. Tavares M, Rezlan E, Vostroknoutova I, Khouadja H, Mebazaa A. New pharmacologic therapies for acute heart failure. Crit Care Med 2008; 36: S112-20.
121. Elkayam U, Tasissa G, Binanay C, et al. Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. Am Heart J 2007; 153: 98-104.
122. Kaheinen P, Pollesello P, Levijoki J, Haikala H. Effects of levosimendan and milrinone on oxygen consumption in isolated guinea-pig heart. J Cardiovasc Pharmacol 2004; 43: 555-61.
123. Banfor PN, Preusser LC, Campbell TJ, et al. Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs. Am J Physiol Heart Circ Physiol 2008; 294: H238-48.
124. Szilagyi S, Pollesello P, Levijoki J, et al. The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig. Eur J Pharmacol 2004; 486: 67-74.
125. Hasenfuss G, Teerlink JR. Cardiac inotropes: current agents and future directions. Eur Heart J 2011; 32: 1838-45.
126. Oldner A, Konrad D, Weitzberg E, Rudehill A, Rosse P, Wanecek M. Effects of levosimendan, a novel inotropic calcium-sensitizing drug, in experimental septic shock. Crit Care Med 2001; 29: 2185-93.
127. Behrends M, Peters J. The calcium sensitizer levosimendan attenuates endotoxin-evoked myocardial dysfunction in isolated guinea pig hearts. Intens Care Med 2003; 29: 1802-7.
128. Morelli A, De Castro S, Teboul J-L, et al. Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intens Care Med 2005; 31: 638-44.
129. Parissis JT, Rafouli-Stergiou P, Stasinos V, Psarogiannakopoulos P, Mebazaa A. Inotropes in cardiac patients: update 2011. Curr Opin Crit Care 2010; 16: 432-41.
130. Yokoshiki H, Sperelakis N. Vasodilating mechanisms of levosimendan. Cardiovasc Drugs Ther 2003; 17: 111-3.
131. Gheorghiade M, Blair JE, Filippatos GS, et al. Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure. J Am Coll Cardiol 2008; 51: 2276-85.
132. Shah SJ, Blair JE, Filippatos GS, et al. Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in Patients Hospitalized with Heart Failure (HORIZON-HF) trial. Am Heart J 2009; 157: 1035-41.
133. Micheletti R, Mattera GG, Rocchetti M, et al. Pharmacological profile of the novel inotropic agent (E, Z)-3-(2-aminoethoxy) imino)androstane-6,17-dione hydrochloride (PST2744). J Pharmacol Exp Therap 2002; 303: 592-600.
134. Malik FI, Hartman JJ, Elias KA, et al. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science 2011; 331: 1439-43.
135. Teerlink JR, Clarke CP, Saikali KG, et al. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study. Lancet 2011; 378: 667-75.
136. Cleland JG, Teerlink JR, Senior R, et al. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet 2011; 378: 676-83.
137. Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation 2005; 111: 2837-49.
138. de Montmollin E, Aboab J, Mansart A, Annane D. Bench-tobedside review: beta-Adrenergic modulation in sepsis. Crit Care 2009; 13: 230.
139. Novotny NM, Lahm T, Markel TA, et al. beta-Blockers in sepsis: reexamining the evidence. Shock 2009; 31: 113-9.
140. Schmittinger CA, Wurzinger B, Deutinger M, et al. How to protect the heart in septic shock: a hypothesis on the pathophysiology and treatment of septic heart failure. Med Hypotheses 2010; 74: 460-5.
141. Ackland GL, Yao ST, Rudiger A, et al. Cardioprotection, attenuated systemic inflammation, and survival benefit of beta1-adrenoceptor blockade in severe sepsis in rats. Crit Care Med 2010; 38: 388-94.
142. Aboab J, Sebille V, Jourdain M, et al. Effects of esmolol on systemic and pulmonary hemodynamics and on oxygenation in pigs with hypodynamic endotoxin shock. Intensive Care Med 2011; 37: 1344-51.
143. Morelli A, Ertmer C, Rehberg S, et al. Heartrate control with esmolol in septic shock: a randomized controlled trial (abstract). Intensive Care Med 2011; S1: 104.
144. Hagiwara S, Iwasaka H, Maeda H, Noguchi T. Landiolol, an ultrashort-acting beta1-adrenoceptor antagonist, has protective effects in an LPS-induced systemic inflammation model. Shock 2009; 31: 515-20.
145. Mori K, Morisaki H, Yajima S, et al. Beta-1 blocker improves survival of septic rats through preservation of gut barrier function. Intensive Care Med 2011; 37: 1849-56.
146. Berk JL, Hagen JF, Beyer WH, Gerber MJ, Dochat GR. The treatment of endotoxin shock by beta adrenergic blockade. Ann Surg 1969; 169: 74-81.
147. Berk JL, Hagen JF, Dunn JM. The role of beta adrenergic blockade in the treatment of septic shock. Surg Gynecol Obstet 1970; 130: 1025-34.
148. Gore DC, Wolfe RR. Hemodynamic and metabolic effects of selective beta1 adrenergic blockade during sepsis. Surgery 2006; 139: 686-94.
149. Dünser M, Haller M, Jochberger S, et al. Beta blocker therapy in patients with septic cardiomyopathy. Intensive Care Med 2007; 33 (Suppl 2): 127.
150. Chen ZM, Pan HC, Chen YP, et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366: 1622-32.
151. Devereaux PJ, Yang H, Yusuf S, et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet 2008; 371: 1839-47.
152. De Ferrari GM, Mazzuero A, Agnesina L, et al. Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure. Eur J Heart Fail 2008; 10: 550-5.
153. Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376: 875-85.
154. Nuding S, Ebelt H, Hoke RS, et al. Reducing elevated heart rate in patients with multiple organ dysfunction syndrome by the I (f) (funny channel current) inhibitor ivabradine: MODI (f)Y Trial. Clin Res Cardiol 2011; 100: 915-23.
155. Hasenfuss G, Maier LS, Hermann HP, et al. Influence of pyruvate on contractile performance and Ca(2+) cycling in isolated failing human myocardium. Circulation 2002; 105: 194-9.
156. Singer M. Mitochondrial function in sepsis: acute phase versus multiple organ failure. Crit Care Med 2007; 35: S441-8.
157. Protti A, Carre J, Frost MT, et al. Succinate recovers mitochondrial oxygen consumption in septic rat skeletal muscle. Crit Care Med 2007; 35: 2150-5.
158. Protti A, Singer M. Bench-to-bedside review: potential strategies to protect or reverse mitochondrial dysfunction in sepsis-induced organ failure. Crit Care 2006; 10: 228.
159. Nisoli E, Clementi E, Paolucci C, et al. Mitochondrial biogenesis: the role of endogenous nitric oxide. Science 2003; 299: 896-9.
160. Kavanagh BP, McCowen KC. Clinical practice. Glycemic control in the ICU. N Engl J Med 2010; 363: 2540-6.
161. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345: 1359-67.
162. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006; 354: 449-61.
163. Finfer S, Chittock DR, Su SY, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360: 1283-97.
164. Engebretsen KM, Kaczmarek KM, Morgan J, Holger JS. High-dose insulin therapy in beta-blocker and calcium channel-blocker poisoning. Clin Toxicol 2011; 49: 277-83.
165. Mehta SR, Yusuf S, Diaz R, et al. Effect of glucose-insulinpotassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA 2005; 293: 437-46.
166. Diaz R, Goyal A, Mehta SR, et al. Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction. JAMA 2007; 298: 2399-405.
167. Bronsveld W, van den Bos GC, Thijs LG. Use of glucose-insulinpotassium (GIK) in human septic shock. Crit Care Med 1985; 13: 566-70.
168. Hamdulay SS, Al-Khafaji A, Montgomery H. Glucose-insulin and potassium infusions in septic shock. Chest 2006; 129: 800-4.
169. Boyer EW, Shannon M. Treatment of calcium-channel-blocker intoxication with insulin infusion. N Engl J Med 2001; 344: 1721-2.
170. Holger JS, Stellpflug SJ, Cole JB, Harris CR, Engebretsen KM. High-dose insulin: a consecutive case series in toxin-induced cardiogenic shock. Clin Toxicol 2011; 49: 653-8.
171. Holger JS, Dries DJ, Barringer KW, Peake BJ, Flottemesch TJ, Marini JJ. Cardiovascular and metabolic effects of high-dose insulin in a porcine septic shock model. Acad Emerg Med 2010; 17: 429-35.